VYNE VYNE Therapeutics Inc.
Healthcare$0.68+0.00%OpenMarket Cap: $11.4M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.17
P/S
24.64
EV/EBITDA
0.55
DCF Value
$0.47
FCF Yield
-230.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.7%
Operating Margin
-5367.6%
Net Margin
-4726.2%
ROE
-69.6%
ROA
-82.9%
ROIC
-98.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $86.0K | 93.0% | $-3.8M | $-3.6M | $— | — |
| Q4 null | $130.0K | 100.0% | $-5.2M | $-4.8M | $— | — |
| FY null | $570.0K | 96.0% | $-29.7M | $-26.5M | $— | — |
| Q3 null | $169.0K | 100.0% | $-7.8M | $-7.3M | $— | — |
| Q2 null | $69.0K | 100.0% | $-7.5M | $-5.8M | $— | — |
| Q1 null | $202.0K | 100.0% | $-9.2M | $-8.6M | $— | — |
| Q4 null | $84.0K | 100.0% | $-12.8M | $-12.0M | $— | — |
| FY null | $501.0K | 100.0% | $-43.6M | $-39.8M | $— | — |
| Q3 null | $121.0K | 100.0% | $-13.1M | $-12.2M | $— | — |
| Q2 null | $198.0K | 100.0% | $-10.4M | $-9.4M | $— | — |
| Q1 null | $98.0K | 100.0% | $-7.4M | $-6.2M | $— | — |
| Q4 2023 | $76.0K | 100.0% | $-6.8M | $-6.2M | $-0.20 | — |